# US 2026/0022420 A1 · Genomic alterations associated with schizophrenia and methods of use thereof for the diagnosis and treatment of the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0022420 A1
- Document ID: US20260022420A1
- Status: Published application
- Kind: A1
- Application number: 19/177,152
- Filed: 2025-04-11
- Published: 2026-01-22
- Earliest claimed: 2008-11-14
- Assignees: The Children's Hospital of Philadelphia
- Applicants: The Children's Hospital of Philadelphia
- Inventors: Hakon Hakonarson; Joseph Glessner; Struan F.A. Grant
- Web page: https://patentgrep.com/patent/US20260022420A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- G01N 33/5058: {Neurological cells}
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2800/302: Schizophrenia
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Compositions and methods for the detection and treatment of schizophrenia are provided.

## Claims

### Claim 1

A method for detecting a propensity for developing schizophrenia, the method comprising: detecting at least one copy number variation (CNV) in a target polynucleotide, wherein if said CNV is present, said patient has an increased risk for developing schizophrenia, and wherein said CNV is:
(a) a deletion containing CNV selected from the group consisting of chr1:194097653-194148082, chr12:84799874-84809923, chr19:471192213-47196345, chr3:60564450-60565103, chr5:78285889-78300897, ch13:81402686-81416252, chr11:88016449-88023261, chr16:68743639-68770545, chr22:17404806-19941349, chr9:140145139-140152969, chr10:42932615-42934354, chr3:4063809-4074877, chr4:9881886-9884092, chr18:38310567-38311765, chr3:61803641-61811383, chr4:135276704-135408238, chr5:2097129-2111366, chr12:60558836-60563972, chr6:57268143-57272458, chr5:52702915-52718131, chr15:32717247-32765105, chr7:142941348-142963649, chr4:114573691-114581335, chr4:162417655-162424561, chr6:162740476-162741040, chr1:92014319-92021028, and chr12:69158942-69164294; or
(b) a duplication containing CNV selected from the group consisting of chr8:26404795-26404795, chr1:174500555-174543675 chr12:18801189-18821605, chr16:29425212-30134444, chr19:426716-434473, chr6:16499554-16508717, and chr15:99980078-100033288.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the target polynucleotide is amplified prior to detection.

### Claim 4 (depends on 1)

The method of claim 1, wherein the step of detecting the presence of said CNV is performed using a process selected from the group consisting of detection of specific hybridization, measurement of allele size, restriction fragment length polymorphism analysis, allele-specific hybridization analysis, single base primer extension reaction, and sequencing of an amplified polynucleotide.

### Claim 5 (depends on 1)

The method of claim 1, wherein the target polynucleotide is DNA.

### Claim 6 (depends on 1)

The method of claim 1, wherein nucleic acids comprising said CNV are obtained from an isolated cell of the human subject.

### Claim at position 7

-14. (canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein said CNV contain a deletion in a gene selected from the group consisting of PDPR, COMT, CACNA1B, RET, SUMF1, WDR1, RIT2, and PIK3C3.

### Claim 16 (depends on 1)

The method of claim 1, wherein said CNV contains a duplication in a gene selected from the group consisting of QPRT, DOC2A, and TBX6.

### Claim at position 10

-21. (canceled)

### Claim 22

A method of treating schizophrenia in a human subject determined to have at least one schizophrenia associated copy number variation (CNV), the method comprising administering to said human subject a therapeutically effective amount of (+)-5-oxo-D-prolinepiperidinamide monohydrate (NS-105).

### Claim at position 12

-26. (canceled)

### Claim 27 (depends on 22)

The method of claim 22, wherein the CNV is at least one selected from the group consisting of:
(a) chr16:68743639-68770545;
(b) chr22:17404806-19941349;
(c) chr16:29425212-30134444;
(d) chr9:140145139-140152969;
(e) chr10:42932615-42934354;
(f) chr3:4063809-4074877;
(g) chr4:9881886-9884092;
(h) chr18:38310567-38311765;
(i) chr12:84799874-84809923;
(j) chr19:47192213-47196345; and
(k) chr11:88016449-88023261.

### Claim 28 (depends on 22)

The method of claim 22, wherein the CNV comprises a deletion in a gene selected from the group consisting of NTS, GRIK5, GRM5, PDPR, COMT, CACNA1B, RET, SUMF1, WDR1, RIT2, and PIK3C3.

### Claim 29 (depends on 22)

The method of claim 22, wherein the CNV comprises a duplication in a gene selected from the group consisting of QPRT, DOC2A, and TBX6.
